US stocks move higher, helped by Facebook, GDP
NEW YORK — It was a stock market turnaround.
Stocks rose sharply Thursday, with large parts of the market erasing losses from the previous day as investors cheered a batch of strong earnings and data that showed the U.S. economy grew at a robust annual rate in the fourth quarter.
Investors also got a welcome respite from the recent turmoil in overseas markets, particularly in Turkey and Argentina.
The Standard &Poor’s 500 index rose 19.99 points, or 1.1 percent, to 1,794.19, with all 10 sectors of the index closing higher. That more than made up the 18.29 points the index lost on Wednesday.
The Nasdaq composite jumped 71.69 points, or 1.8 percent, to 4,123.13 and the Dow Jones industrial average rose 109.82 points, or 0.7 percent, to 15,848.61.
Investors welcomed news that the U.S. economy grew at a 3.2 percent annual rate in the final three months of 2013, a positive sign for the economy in 2014. Consumer spending, a major driver of the U.S. economy, picked up in the quarter.
“It was a good, balanced GDP report,” said Sean Lynch, global investment strategist with Wells Fargo Private Bank, which manages $170 billion in assets.
Good news from a big technology player also boosted the market. Facebook jumped $7.55, or 14 percent, to $61.08. The social media company reported results late Wednesday that exceeded the expectations of financial analysts. Facebook’s adjusted profit was 31 cents per share, four cents better than forecast.
It wasn’t all good news out of the technology sector. Amazon.com sank in after-hours trading after releasing results that fell short of what investors were expecting. The stock of the online retailing pioneer fell $13 or 3.2 percent, to $403.01 about 90 minutes after the market close.
In other earnings news, Visa rose $3.76, or 2 percent, to $220.88 after the company reported a 9 percent rise in first-quarter profits, beating expectations.
Alexion Pharmaceuticals was the biggest advancer in the S&P 500, rising $28.27, or 21 percent, to $162 after the company also beat analysts’ expectations and gave a strong 2014 outlook. Alexion is a specialized drug maker focused on rare genetic diseases.
The company helped lift the stocks of other drugmakers. Dow members Merck and Pfizer each rose more than 2 percent. Specialized drugmakers Gilead Sciences and Biogen were up 2 percent and 4 percent, respectively.
Even with Thursday’s gains, it’s been a difficult month for investors. The Dow is down 4.4 percent in January, the worst start to a year since 2009.
Rules for posting comments
Comments posted below are from readers. In no way do they represent the view of Stephens Media LLC or this newspaper. This is a public forum.
Comments may be monitored for inappropriate content but the newspaper is under no obligation to do so. Comment posters are solely responsible under the Communications Decency Act for comments posted on this Web site. Stephens Media LLC is not liable for messages from third parties.
IP and email addresses of persons who post are not treated as confidential records and will be disclosed in response to valid legal process.
Do not post:
- Potentially libelous statements or damaging innuendo.
- Obscene, explicit, or racist language.
- Copyrighted materials of any sort without the express permission of the copyright holder.
- Personal attacks, insults or threats.
- The use of another person's real name to disguise your identity.
- Comments unrelated to the story.
If you believe that a commenter has not followed these guidelines, please click the FLAG icon below the comment.